Cancer Drug Resistance

ISBN-13: 9781588295309 / Angielski / Twarda / 2006 / 636 str.

Beverly A. Teicher

Opis

Leading experts summarize and synthesize the latest discoveries concerning the changes that occur in tumor cells as they develop resistance to anticancer drugs, and suggest new approaches to preventing and overcoming it. The authors review physiological resistance based upon tumor architecture, cellular resistance based on drug transport, epigenetic changes that neutralize or bypass drug cytotoxicity, and genetic changes that alter drug target molecules by decreasing or eliminating drug binding and efficacy. Highlights include new insights into resistance to antiangiogenic therapies, oncogenes and tumor suppressor genes in therapeutic resistance, cancer stem cells, and the development of more effective therapies. There are also new findings on tumor immune escape mechanisms, gene amplification in drug resistance, the molecular determinants of multidrug resistance, and resistance to taxanes and Herceptin.

Recenzje

"...a resource to scientists of diverse specialties with interests relating to the repsonse of malignant disease to current and experimental therapies." - Neoplasma

"...an excellent book that is appropriate for scientists and clinicians with an interest in the basis of anticancer drug resistance." -Doody's Book Review, Weighted Numberical Score: 90 - 4 Stars!

Spis treści

Part I. Physiological Resistance The Cycle Between Angiogenesis, Perfusion, and Hypoxia in Tumors Mark W. Dewhirst, Yiting Cao, Benjamin Moeller, and Chuan-Yuan Li Influence of Tumor pH on Therapeutic Response Chang W. Song, Robert Griffin, and Heon Joo Park Tumor Oxygenation and Treatment Response Sarah Jane Lunt and Richard P. Hill Oncogenes and Tumor Suppressor Genes in Therapeutic Resistance: The Role of Evolving Interrelationships Between Cancer Cells and Host Tissues Janusz W. Rak, Brenda Coomber, and Joanne L. Yu PET Imaging of Response and Resistance to Cancer Therapy David A. Mankoff and Kenneth A. Krohn Part II: Biological Resistance Cancer Stem Cells: Implications for Development of More Effective Therapies Ilia Mantle, Gabriela Dontu, Suling Liu, and Max S. Wicha Therapeutic Resistance in Leukemia William R. Waud Tumor Site Implantation and Animal Model Selection in Oncology Anibal A. Arjona and Enrique Alvarez In Vivo Resistance Beverly A. Teicher Characteristics of the Metastatic Phenotype: The Melanoma Experience Vladislava O. Melnikova and Menashe Bar-Eli The Microenvironment and Drug Resistance Patrice J. Morin Part III. Biochemical Resistance Glutathione and Glutathione S-Transferases in Drug Resistance Victoria J. Findlay, Danyelle M. Townsend, and Kenneth D. Tew Metallothioneins in Drug Resistance Faiyaz Notta and D. James Koropatnick Molecular Determinants of Intrinsic Multidrug Resistance in Cancer Cells and Tumors Elena Monti New and Revised Concepts in Multidrug Resistance: Sestamibi, SNPs, Substrates, and Stem Cells Susan E. Bates, John Deeken, Chaohong Fan, and Robert W. Robey Cisplatin Resistance: Molecular Basis of a Multifaceted Impediment Zahid H. Siddik Regulation of the Cellular Pharmacology and Cytotoxicity of Cisplatin by Copper Transporters Roohangiz Safaei and Stephen B. Howell Resistance to Taxanes Lee M. Greenberger and Deepak Sampath CpG Island Methylation and Drug Resistance Jens M. Teodoridis and Robert Brown De Novo and Acquired Resistance to Antitumor Alkylating Agents Lori A. Hazlehurst and William S. Dalton Resistance to Antiangiogenic Agents George W. Sledge, Jr., Kathy D. Miller, Bryan Schneider, and Christopher J. Sweeney Part IV. The Role of Hormones, Growth Factors, and Oncogenes Resistance to Antiestrogens Clodia Osipo and Ruth M. O'Regan Mechanisms of Glucocorticoid Actions and Resistance in Multiple Myeloma Varsha Gandhi and Beatriz Sanchez-Vega Herceptin Resistance Ingrid A. Mayer and Carlos L. Arteaga Role of TGF-b in Tumor Progression and Metastasis Jan Pinkas and Beverly A. Teicher p53-Based Immunotherapy of Cancer Albert B. DeLeo Response and Resistance to Ionizing Radiation Paul Dent, Adly Yacoub, Michael P. Hagan, and Steven Grant Amplification in DNA Copy Numbers as a Mechanism of Acquired Drug Resistance M. Jim Yen, Ie-Ming Shih, Victor E. Velculescu, and Tian-Li Wang Part V. Clinical Aspects of Resistance Cancer Chemotherapy: Clinical Evidence for Drug Resistance Mika A. Sovak and David R. Spriggs Molecular Profiling in Breast Cancer: Genomic Approaches Toward Tailored Cancer Therapies Kristin Kee and Jeffrey E. Green Tumor Immune Escape Mechanisms Yi Ting Koh, M. Luz García-Hernández, and W. Martin Kast Index

O autorze

Cancer Drug Resistance represents a point on the path of the long journey toward understanding the complex interactions between host, tumor and cytotoxic or immunomodulatory agents. It addresses the resistance of solid tumors to anticancer therapeutics by considering mechanisms that involve alterations in genetics and epigenetics, cellular biochemistry, properties related to physiology of the solid tumor mass and alterations in host metabolic and immune status induced by the presence of malignant disease.

Blurb

As genomic techniques gradually reveal the ability of malignant cells to respond to chemical and biological insults with remarkable flexibility of phenotype, it becomes clear that much remains to be done to control and eliminate such cells. In Cancer Drug Resistance, leading scientists from the best academic institutions and industrial laboratories summarize and synthesize the latest discoveries concerning the changes that occur in tumor cells as they develop resistance to a wide variety of anticancer therapeutics, as well as suggest new approaches to the biology of drug resistance that may afford new therapeutic opportunities. The authors review physiological resistance based tumor architecture, cellular resistance based on drug transport, epigenetic changes that neutralize or bypass drug cytotoxicity, and genetic changes that alter drug target molecules by decreasing or eliminating drug binding and efficacy. Highlights include new insights into resistance to antiangiogenic therapies, oncogenes and tumor suppressor genes in therapeutic resistance, cancer stem cells, and the development of more effective therapies. There are also new findings on tumor immune escape mechanisms, gene amplification in drug resistance, the molecular determinants of multidrug resistance, and resistance to taxanes and Herceptin®.
Authoritative and insightful, Cancer Drug Resistance offers basic and clinical investigators a state-of-the-art synthesis of the many faceted research now available on the biology and genetics of tumor resistance, as well as exciting new approaches to its prevention and eradication.